JP2009518312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518312A5 JP2009518312A5 JP2008543545A JP2008543545A JP2009518312A5 JP 2009518312 A5 JP2009518312 A5 JP 2009518312A5 JP 2008543545 A JP2008543545 A JP 2008543545A JP 2008543545 A JP2008543545 A JP 2008543545A JP 2009518312 A5 JP2009518312 A5 JP 2009518312A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- plant exudate
- plant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000416 exudates and transudate Anatomy 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 244000005700 microbiome Species 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000003223 protective agent Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74177405P | 2005-12-02 | 2005-12-02 | |
| PCT/US2006/046320 WO2007065024A2 (en) | 2005-12-02 | 2006-12-04 | Composition and use of phyto-percolate for treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518312A JP2009518312A (ja) | 2009-05-07 |
| JP2009518312A5 true JP2009518312A5 (https=) | 2011-03-03 |
Family
ID=38092904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543545A Pending JP2009518312A (ja) | 2005-12-02 | 2006-12-04 | 疾患を治療するための植物浸出物の組成物および使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1954800A4 (https=) |
| JP (1) | JP2009518312A (https=) |
| AU (1) | AU2006320264A1 (https=) |
| CA (1) | CA2631773C (https=) |
| WO (1) | WO2007065024A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10166270B2 (en) | 2004-04-23 | 2019-01-01 | Zivo Bioscience, Inc. | Composition and method for affecting cytokines and NF-κB |
| US7807622B2 (en) | 2004-04-23 | 2010-10-05 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| US8586053B2 (en) | 2005-09-21 | 2013-11-19 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| JP2013510905A (ja) * | 2009-11-16 | 2013-03-28 | ヘルス エンハンスメント プロダクツ インク | サイトカイン及びｎｆ−ｋｂに影響を与える組成物及び方法 |
| JP2013520444A (ja) | 2010-02-22 | 2013-06-06 | ヘルス エンハンスメント プロダクツ インコーポレイテッド | 高コレステロール血症を処置するための薬剤及び機序 |
| AU2014252808A1 (en) * | 2013-04-09 | 2015-11-12 | Cresset Biomolecular Discovery Ltd | The treatment of inflammatory disorders |
| US10232028B2 (en) | 2013-06-13 | 2019-03-19 | Zivo Bioscience, Inc. | Compounds and methods for affecting cytokines |
| WO2016133922A1 (en) | 2015-02-16 | 2016-08-25 | Zivo Bioscience, Inc. | Methods of modulating immune and inflammatory responses via administration of an algal biomass |
| US11806375B2 (en) | 2016-02-16 | 2023-11-07 | Zivo Bioscience, Inc. | Nutritional support for animals via administration of an algal derived supplement |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE265218T1 (de) * | 2000-08-10 | 2004-05-15 | Ocean Nutrition Canada Ltd | Chlorella zubereitungen mit immunmodulatorischen eigenschaften |
| US20080031863A1 (en) * | 2004-04-23 | 2008-02-07 | Health Enhancement Products, Inc. | Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease |
-
2006
- 2006-12-04 CA CA2631773A patent/CA2631773C/en active Active
- 2006-12-04 EP EP06838974A patent/EP1954800A4/en not_active Withdrawn
- 2006-12-04 JP JP2008543545A patent/JP2009518312A/ja active Pending
- 2006-12-04 AU AU2006320264A patent/AU2006320264A1/en not_active Abandoned
- 2006-12-04 WO PCT/US2006/046320 patent/WO2007065024A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| González-Chávez et al. | Lactoferrin: structure, function and applications | |
| Joosten et al. | Novel insights into the biology of interleukin-32 | |
| Tanno et al. | Invariant NKT cells promote skin wound healing by preventing a prolonged neutrophilic inflammatory response | |
| Locati et al. | Macrophage activation and polarization as an adaptive component of innate immunity | |
| Herbert et al. | Arginase I suppresses IL-12/IL-23p40–driven intestinal inflammation during acute schistosomiasis | |
| Steidler et al. | Therapeutic drug delivery by genetically modified Lactococcus lactis | |
| Wang et al. | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice | |
| George et al. | Host anti-microbial response to Helicobacter pylori infection | |
| Schwartz et al. | Interleukin 33: An innate alarm for adaptive responses beyond Th2 immunity–emerging roles in obesity, intestinal inflammation, and cancer | |
| Kumar et al. | IL-22: an evolutionary missing-link authenticating the role of the immune system in tissue regeneration | |
| Kelly et al. | Staphylococcus aureus-induced immunosuppression mediated by IL-10 and IL-27 facilitates nasal colonisation | |
| WO2008076915A8 (en) | Treatment of pigs with pcv2 antigen | |
| US20230048366A1 (en) | Combination therapy for treating or preventing cancer | |
| JP2009518312A5 (https=) | ||
| JP2012515213A5 (https=) | ||
| Takakura et al. | Influences of orally administered lactoferrin on IFN-γ and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells | |
| GB2453491A (en) | Immunogenic proteins of burkholderia pseudomallei and uses thereof | |
| US20230277602A1 (en) | Combination therapy for treating or preventing cancer | |
| EP2892917B1 (en) | Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders | |
| Puddu et al. | Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages | |
| Yang et al. | Interferon-γ-producing B cells induce the formation of gastric lymphoid follicles after Helicobacter suis infection | |
| Yang et al. | Saccharomyces boulardii administration can inhibit the formation of gastric lymphoid follicles induced by Helicobacter suis infection | |
| Shahid et al. | Murine and human cathelicidins contribute differently to hallmarks of mastitis induced by pathogenic Prototheca bovis algae | |
| Kobayashi et al. | The anti-atherosclerotic dipeptide, Trp-His, reduces intestinal inflammation through the blockade of L-type Ca2+ channels | |
| Yu et al. | NLRP3 inflammasome signal pathway involves in Vibrio harveyi-induced inflammatory response in murine peritoneal macrophages in vitro |